对阿尔茨海默氏症疾病的分子研究
1Internal and Subintensive Medicine Department, Azienda Ospedaliero-Universitaria delle Marche, 60131 Ancona, Italy.
Biomedicines
|July 29, 2023
概括
阿尔茨海默病 (AD) 是一种进展性神经退行性疾病. 研究正在探索新的治疗点,以对抗这种流行形式的痴呆症.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学研究生物医学研究
背景情况:
- 阿尔茨海默病 (AD) 是全球痴呆的主要原因.
- 阿尔茨海默病的特征是渐进的神经退行,它显著影响认知功能.
- 目前的治疗策略提供症状缓解,但不能阻止疾病的进展.
研究的目的:
- 研究驱动阿尔茨海默病进展的分子和细胞机制.
- 识别和评估潜在的治疗目标,以减轻AD病理和认知衰退.
主要方法:
- 关于阿尔茨海默病的当前文献的综述.
- 对临床前和临床研究的分析,重点关注AD生物标志物和治疗方法.
- 综合了有关AD相关的遗传,环境和生活方式因素的数据.
主要成果:
- 阿尔茨海默病的主要病理特征包括粉样质斑块和神经纤维状结.
- 遗传因素,如APOE ε4,显著增加AD风险.
- 新兴的治疗策略针对的是粉样β,和神经炎症.
结论:
- 早期诊断和干预对于管理阿尔茨海默病至关重要.
- 多目标治疗方法对未来的AD治疗有希望.
- 持续的研究对于对抗全球不断增长的阿尔茨海默病负担至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
01:22Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218